BACKGROUND: Both liver transplantation (LT) and liver resection (LR) represent curative treatment options for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. In this study, we have compared outcomes between historical and more recent patient cohorts scheduled either for LT or LR, respectively. METHODS: Clinicopathological data of all patients with HCC and cirrhosis who underwent LT or LR between 1989 and 2011 were evaluated. Overall survival of patients with HCC within the Milan criteria (MC) was analyzed focusing on changes between different time periods. RESULTS: In total, 364 and 141 patients underwent LT and LR for HCC in cirrhosis, respectively. Among patients with HCC within MC, 214 and 59 underwent LT and LR, respectively. Postoperative morbidity (37 vs. 11%, P < .0001), but not mortality (3 vs. 1%, P = .165), was higher after LR than after LT for HCC within MC. In the period 1989-2004, overall survival (OS) was significantly higher in patients who underwent LT compared to LR for HCC within MC (5-year OS: 77 vs. 36%, P < .0001). Interestingly, in the more recent period 2005-2011, OS was comparable between LT and LR for HCC within MC (5-year OS: 73 vs. 61%, P = .07). CONCLUSION: We have noted an improvement of outcomes among patients selected for partial hepatectomy in recent years that were comparable to stable results after LT in cirrhotic patients with HCC. Whether those improvements are due to advances in liver surgery, optimized perioperative managament for patients with liver cirrhosis, and the development of modern multimodal treatment strategies for the recurrent lesions appears plausible.
BACKGROUND: Both liver transplantation (LT) and liver resection (LR) represent curative treatment options for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. In this study, we have compared outcomes between historical and more recent patient cohorts scheduled either for LT or LR, respectively. METHODS: Clinicopathological data of all patients with HCC and cirrhosis who underwent LT or LR between 1989 and 2011 were evaluated. Overall survival of patients with HCC within the Milan criteria (MC) was analyzed focusing on changes between different time periods. RESULTS: In total, 364 and 141 patients underwent LT and LR for HCC in cirrhosis, respectively. Among patients with HCC within MC, 214 and 59 underwent LT and LR, respectively. Postoperative morbidity (37 vs. 11%, P < .0001), but not mortality (3 vs. 1%, P = .165), was higher after LR than after LT for HCC within MC. In the period 1989-2004, overall survival (OS) was significantly higher in patients who underwent LT compared to LR for HCC within MC (5-year OS: 77 vs. 36%, P < .0001). Interestingly, in the more recent period 2005-2011, OS was comparable between LT and LR for HCC within MC (5-year OS: 73 vs. 61%, P = .07). CONCLUSION: We have noted an improvement of outcomes among patients selected for partial hepatectomy in recent years that were comparable to stable results after LT in cirrhoticpatients with HCC. Whether those improvements are due to advances in liver surgery, optimized perioperative managament for patients with liver cirrhosis, and the development of modern multimodal treatment strategies for the recurrent lesions appears plausible.
Authors: Andreas Andreou; Safak Gül; Andreas Pascher; Wenzel Schöning; Hussein Al-Abadi; Marcus Bahra; Fritz Klein; Timm Denecke; Benjamin Strücker; Gero Puhl; Johann Pratschke; Daniel Seehofer Journal: HPB (Oxford) Date: 2014-09-28 Impact factor: 3.647
Authors: Maximilian Jara; Tim Reese; Maciej Malinowski; Erika Valle; Daniel Seehofer; Gero Puhl; Peter Neuhaus; Johann Pratschke; Martin Stockmann Journal: HPB (Oxford) Date: 2015-07 Impact factor: 3.647
Authors: Yoji Kishi; Eddie K Abdalla; Yun Shin Chun; Daria Zorzi; David C Madoff; Michael J Wallace; Steven A Curley; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Zheng Zheng; Wenhua Liang; Daniel P Milgrom; Zhouying Zheng; Paul M Schroder; Ning S Kong; Changsheng Yang; Zhiyong Guo; Xiaoshun He Journal: Transplantation Date: 2014-01-27 Impact factor: 4.939
Authors: Riccardo Lencioni; Thierry de Baere; Michael C Soulen; William S Rilling; Jean-Francois H Geschwind Journal: Hepatology Date: 2016-03-07 Impact factor: 17.425
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Jin Hean Koh; Darren Jun Hao Tan; Yuki Ong; Wen Hui Lim; Cheng Han Ng; Phoebe Wen Lin Tay; Jie Ning Yong; Mark D Muthiah; Eunice X Tan; Ning Qi Pang; Beom Kyung Kim; Nicholas Syn; Alfred Kow; Brian K P Goh; Daniel Q Huang Journal: Hepatobiliary Surg Nutr Date: 2022-02 Impact factor: 8.265
Authors: Safak Gül-Klein; Anika Kästner; Philipp Konstantin Haber; Felix Krenzien; Simon Wabitsch; Alexander Krannich; Andreas Andreou; Dennis Eurich; Frank Tacke; David Horst; Johann Pratschke; Moritz Schmelzle Journal: J Hepatocell Carcinoma Date: 2021-03-18
Authors: Felix Krenzien; Eriselda Keshi; Katrin Splith; Silvan Griesel; Kaan Kamali; Igor M Sauer; Linda Feldbrügge; Johann Pratschke; Annekatrin Leder; Moritz Schmelzle Journal: Front Immunol Date: 2019-04-11 Impact factor: 7.561
Authors: Philipp K Haber; Christoph Maier; Anika Kästner; Linda Feldbrügge; Santiago Andres Ortiz Galindo; Dominik Geisel; Uli Fehrenbach; Matthias Biebl; Felix Krenzien; Christian Benzing; Wenzel Schöning; Johann Pratschke; Moritz Schmelzle Journal: J Clin Med Date: 2021-02-10 Impact factor: 4.241